Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated with Interferon-Free, Direct-Acting Antiviral Regimens

Clinical Infectious Diseases

Volumn 61, Issue 6, 2015, Pages 974-977

  Harrington, Patrick R ^a   Fleischer, Russell ^a   Connelly, Sarah M ^a   Lewis, Linda L ^a   Murray, Jeffrey ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

direct acting antiviral agents; HCV; lymphocytes; ribavirin

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC HEPATITIS C; CLINICAL TRIAL (TOPIC); HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LYMPHOCYTE COUNT; MIXED INFECTION; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS TYPING; CHEMICALLY INDUCED; CONTROLLED STUDY; HEPATITIS C, CHRONIC; IMMUNOLOGY; LYMPHOCYTOPENIA; RANDOMIZED CONTROLLED TRIAL;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; LYMPHOCYTE COUNT; LYMPHOPENIA; RIBAVIRIN;

EID: 84940647614     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ419     Document Type: Article

References (12)

1. American Association for the Study of Liver Diseases/Infectious Diseases Society of America/International AIDS Society-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed 22 December 2014.
2. US Food and Drug Administration. Sofosbuvir prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204671s001lbl.pdf. Accessed 5 January 2015.
3. US Food and Drug Administration. Ledipasvir/sofosbuvir prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205834s000lbl.pdf. Accessed 5 January 2015.
4. US Food and Drug Administration. Ombitasvir/paritaprevir/ritonavir/dasabuvir prescribing information. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2014/206619lbl.pdf. Accessed 5 January 2015.
5. US Food and Drug Administration. Simeprevir prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205123s002lbledt.pdf. Accessed 5 January 2015.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
7. Melia MT, Braü N, Poordad F, et al. Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. Clin Infect Dis 2014; 58:960-9.
8. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-61.
9. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.
10. Afdhal N, Reddy KR, Nelson DR, et al. Lepipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
11. Wyles D, Sulkowski MS, Eron JJ, et al. 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin, 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2014. Hepatology 2014; 60:1136-7A.
12. Alqahtani S, Afdhal N, Zeuzem S, et al. Safety of ledipasvir/sofosbuvir with and without ribavirin for the treatment of patients with chronic HCV genotype 1 infection: an analysis of the phase 3 ION trials, 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2014. Hepatology 2014; 60:1140A.